Miphic offers a high‑throughput, imaging‑based platform that quantifies mitochondrial function in low‑cell‑number samples across up to 96 conditions in a single experiment. The service supports metabolic drug discovery, personalized medicine by testing patient‑derived cells, and fundamental research on mitochondrial responses, with customizable assay design and optional machine‑learning analysis.
Funding
Funding not disclosed
Founders
Product
Problem
Mitochondrial dysfunction underlies many diseases, yet clinicians and researchers lack rapid, quantitative tools to assess mitochondrial activity in patient cells or experimental models. This gap limits the ability to select effective metabolic therapies, discover new drugs, and understand disease mechanisms.
Solution
Miphic provides a high‑throughput, imaging‑based platform that quantifies mitochondrial function across up to 96 conditions in a single experiment. By measuring parameters such as respiration, membrane potential, and reactive oxygen species in low‑cell‑number samples, the service delivers detailed functional profiles for drug libraries, patient‑derived cells, or genetic perturbations. The platform supports three use cases: metabolic drug discovery (screening libraries, mechanism‑of‑action studies, and synergistic combinations), personalized medicine (identifying the most effective metabolic drug for an individual’s cells), and fundamental metabolism research (probing responses to metabolites, stressors, or mutations). Results are delivered with customizable reporting and optional machine‑learning models for large‑scale data analysis, enabling rapid decision‑making without the need for bulk assays.
Target Audience
Primary customers are pharmaceutical and biotech companies conducting metabolic drug discovery, clinical researchers seeking patient‑specific therapeutic guidance, and academic labs studying mitochondrial biology and disease mechanisms.
Features
- Imaging‑based multiparametric readout of mitochondrial activity (e.g., respiration, membrane potential, ROS) on a per‑cell basis
- High‑throughput capacity to test up to 96 conditions simultaneously, including multiple drugs, concentrations, metabolites, or patient samples
- Low cell‑number requirement, allowing analysis of scarce primary or patient‑derived cells
- Fully customizable assay design to match specific scientific or clinical questions
- Integrated data analysis pipeline with optional machine‑learning modeling for pattern detection and predictive insights
- Capability to assess drug mechanisms, synergistic combinations, and genotype‑specific responses